Cargando…

Development of the ATAQ-IPF: a tool to assess quality of life in IPF

BACKGROUND: There is no disease-specific instrument to assess health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF). METHODS: Patients' perspectives were collected to develop domains and items for an IPF-specific HRQL instrument. We used item variance and Ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swigris, Jeffrey J, Wilson, Sandra R, Green, Kathy E, Sprunger, David B, Brown, Kevin K, Wamboldt, Frederick S
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920246/ https://www.ncbi.nlm.nih.gov/pubmed/20673370 http://dx.doi.org/10.1186/1477-7525-8-77

Ejemplares similares

Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA)
por: Yorke, Janelle, et al.
Publicado: (2014)

Development of ATAQ-LAM: a tool to assess quality of life in Lymphangioleiomyomatosis
por: Walker, Tarik D., et al.
Publicado: (2015)

Mitochondrial Quality Control in COPD and IPF
por: Hara, Hiromichi, et al.
Publicado: (2018)

Recommendations on treatment for IPF
por: Behr, Jürgen, et al.
Publicado: (2013)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
por: Jo, Helen E., et al.
Publicado: (2019)

Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF
por: Tóth, Nóra Melinda, et al.
Publicado: (2023)

Highlights of HRCT imaging in IPF
por: Sverzellati, N
Publicado: (2013)

IPF - Idiopathic Pulmonary Fibrosis
Publicado: (2019)

The role of neutrophils in the pathogenesis of IPF
por: Jegal, Yangjin
Publicado: (2022)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry
por: Kreuter, Michael, et al.
Publicado: (2017)

Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior
por: Khine, Ngu, et al.
Publicado: (2020)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
por: Barratt, Shaney L., et al.
Publicado: (2018)

The Role of Immunity and Inflammation in IPF Pathogenesis
por: Butler, Marcus W., et al.
Publicado: (2018)

Senescent Cells in IPF: Locked in Repair?
por: Meiners, Silke, et al.
Publicado: (2020)

IPF in Saudi Arabia: Lessons for all
por: Nathan, Steven D.
Publicado: (2020)

Microbiota and IPF: hidden and detected relationships
por: Fabbrizzi, Alessio, et al.
Publicado: (2021)

Radiological and Physiological Predictors of IPF Mortality
por: Kishaba, Tomoo, et al.
Publicado: (2021)

Moving senolytics closer to the clinic in IPF
por: Kramer, Daniel, et al.
Publicado: (2023)

Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates
por: Hoyer, Nils, et al.
Publicado: (2022)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

The Role of Cardiopulmonary Exercise Test in IPF Prognosis
por: Triantafillidou, Christina, et al.
Publicado: (2013)

Opioids: an unexplored option for treatment of dyspnea in IPF
por: Kohberg, Charlotte, et al.
Publicado: (2016)

Evolving Perspectives on Innate Immune Mechanisms of IPF
por: Ishikawa, Genta, et al.
Publicado: (2021)

IPF-Acute Exacerbations: Advances and Future Perspectives
por: Papiris, Spyros A., et al.
Publicado: (2022)

IPF Respiratory Symptoms Management — Current Evidence
por: Janowiak, Piotr, et al.
Publicado: (2022)

Epigenetic regulation of IPF fibroblast phenotype by glutaminolysis
por: Xiang, Zheyi, et al.
Publicado: (2022)

Histopathological evaluation of autopsy cases with isolated pulmonary fat embolism (IPFE): is cardiopulmonary resuscitation a main cause of death in IPFE?
por: Turkmen Samdanci, Emine, et al.
Publicado: (2019)

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
por: Durheim, Michael T, et al.
Publicado: (2020)

Understanding the informational needs of patients with IPF and their caregivers: ‘You get diagnosed, and you ask this question right away, what does this mean?’
por: Ramadurai, Deepa, et al.
Publicado: (2018)

The pathogenesis of COPD and IPF: Distinct horns of the same devil?
por: Chilosi, Marco, et al.
Publicado: (2012)

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012)

Regulation of TERRA on telomeric and mitochondrial functions in IPF pathogenesis
por: Gao, Yulin, et al.
Publicado: (2017)

Imaging Review of the Lung Parenchymal Complications in Patients with IPF
por: Baratella, Elisa, et al.
Publicado: (2019)

Diffuse alveolar hemorrhage complicating acute exacerbation of IPF
por: Murohashi, Kota, et al.
Publicado: (2020)

Severe Fatigue is Highly Prevalent in Patients with IPF or Sarcoidosis
por: Bloem, Ada E. M., et al.
Publicado: (2020)

Multiple complications of advanced IPF in an individual patient presentation
por: Ledger, Thomas, et al.
Publicado: (2023)

Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF)
por: Boon, Kathy, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_vruq367m2otukrrplei9qp5cg0